Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Black Diamond emerges from stealth mode with $20mm Series A from Versant

Executive Summary

Versant Ventures launched precision cancer medicine company Black Diamond Therapeutics Inc. and provided the company with $20mm in Series A funds. Black Diamond emerges from stealth mode with the funding, and is using its MAP (mutation, allostery, and pharmacology) platform to discover and target allosteric mutant oncogenes. The platform has so far produced five compounds, and with the current financing (and further funds expected in 2019), the company plans to advance three into clinical trials within the next two years. Series A proceeds will also help Black Diamond establish operations in Toronto, Canada.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies